Imunon, Inc.
CLSN
Rank in Stocks
#34972
Imunon, Inc. is a biotechnology firm in the clinical development stage,... Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.
Share Price
$1.96
Last synced: 2022-09-20
Market Cap
$4.46M
Change (1 day)
0.00%
Change (1 year)
122.70%
Country
US
Trade Imunon, Inc. (CLSN)
Category
Healthcare
Market Capitalization of Imunon, Inc.(CLSN)
Market Cap: $4.46M
As of October 2026 Imunon, Inc. has a market cap of $4.46M. This makes Imunon, Inc. the world's 34972nd most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Imunon, Inc. from 2018 to 2026
CLSN compared with Top 5 Most Popular stocks
